ALTG 16/005 OSCILLATE: Alternating Osimertinib and Gefitinib in patients with EGFR T790M positive NSCLC – B Solomon

This study aims to determine the efficacy, safety, and feasibility of alternating osimertinib and gefitinib in patients with EGFR-T790M mutation positive NSCLC. Planned recruitment is 45 patients from 15 sites. The protocol has been finalised and funding approved. Central ethics submission was completed in March 2017, feasibility will be circulated in Q2 2017 and the anticipated FPI will be in Q3 2017.

Contact: OSCILLATE@ctc.usyd.edu.au

Upcoming Events

28 August 2017 12.00am TACT Board Teleconference (closed)
8 September 2017 12.00am ESMO 2017 Congress, Madrid Spain
6 October 2017 12.00am ***UPDATED*** 3rd ALTG Preceptorship in Lung Cancer, Melbourne VIC
15 October 2017 12.00am TACT General Assembly (closed), Yokohama Japan
15 October 2017 12.00am 18th WCLC, Yokohama Japan
24 November 2017 12.00am ***UPDATED*** 2017 ALTG Lung Cancer Symposium, Sydney NSW
24 November 2017 12.00am ***UPDATED*** ALTG Members’ Meeting, Sydney NSW